Kainos Laboratories, Inc. (JP:4556)
:4556
Want to see JP:4556 full AI Analyst Report?
Top Page
Kainos Laboratories, Inc.
(4556)
Select Model
Select Model
Rating:64Neutral
Price Target:
¥2,427.00
▲(90.95% Upside)
Action:Downgraded
Date:06/11/26
The score is primarily supported by solid financial strength (low leverage and steady revenue growth), but it is held back by the recent drop in profitability and softer free-cash-flow trend. Technicals are neutral-to-mildly supportive, while the high P/E and modest dividend yield are a meaningful valuation headwind.
Positive Factors
Conservative Balance Sheet
A very low debt-to-equity (~0.08) and an improving equity base provide durable financial flexibility. This conservative capital structure supports continued R&D, working-capital needs and resilience to sector cycles, reducing refinancing and solvency risk over the next 2–6 months.
Negative Factors
Profitability Decline
A material fall in net margin signals rising costs or adverse product mix that may persist beyond a single year. Lower margin conversion reduces retained earnings and the firm's capacity to self-fund growth, potentially forcing trade-offs between investment, dividends and margin restoration.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
A very low debt-to-equity (~0.08) and an improving equity base provide durable financial flexibility. This conservative capital structure supports continued R&D, working-capital needs and resilience to sector cycles, reducing refinancing and solvency risk over the next 2–6 months.
Read all positive factors
Kainos Laboratories, Inc. (4556) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.28B
Dividend Yield2.53%
Average Volume (3M)3.67K
Price to Earnings (P/E)55.9
Beta (1Y)0.54
Revenue Growth3.28%
EPS Growth-30.16%
CountryJP
Employees133
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)33.54
Shares Outstanding4,558,860
10 Day Avg. Volume3,280
30 Day Avg. Volume3,666
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)1.32
Price to Sales (P/S)1.75
P/FCF Ratio17.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kainos Laboratories, Inc. Business Overview & Revenue Model
Company Description
Based in Tokyo, Japan, KAINOS Laboratories, Inc. specializes in the research, development, production, commercialization, and global trade of various items. Its extensive portfolio encompasses pharmaceuticals, diagnostic agents, and associated che...
How the Company Makes Money
null...
Kainos Laboratories, Inc. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
86
Very Positive
Cash Flow
63
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.48B | 5.31B | 5.06B | 4.92B | 4.61B |
| Gross Profit | 2.53B | 2.61B | 2.48B | 2.45B | 2.35B |
| EBITDA | 850.06M | 919.48M | 977.00M | 956.45M | 897.86M |
| Net Income | 449.15M | 641.02M | 637.97M | 568.17M | 512.33M |
Balance Sheet | |||||
| Total Assets | 9.57B | 8.83B | 8.61B | 8.12B | 7.57B |
| Cash, Cash Equivalents and Short-Term Investments | 4.17B | 3.40B | 3.17B | 3.02B | 2.68B |
| Total Debt | 603.08M | 629.49M | 862.97M | 941.10M | 947.61M |
| Total Liabilities | 2.33B | 2.06B | 2.34B | 2.45B | 2.37B |
| Stockholders Equity | 7.24B | 6.78B | 6.27B | 5.67B | 5.20B |
Cash Flow | |||||
| Free Cash Flow | 548.72M | 633.30M | 356.87M | 536.81M | 463.19M |
| Operating Cash Flow | 553.74M | 704.78M | 430.58M | 544.51M | 604.36M |
| Investing Cash Flow | -27.35M | -71.30M | -72.83M | -10.33M | -141.19M |
| Financing Cash Flow | -182.29M | -411.04M | -203.73M | -191.14M | -31.25M |
Kainos Laboratories, Inc. Technical Analysis
Neutral
1271.00
Price Trends
2269.04
Negative
2099.68
Positive
1686.63
Positive
Market Momentum
0.93
Positive
51.96
Neutral
77.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4556, the sentiment is Neutral. The current price of 1271 is below the 20-day moving average (MA) of 2270.05, below the 50-day MA of 2269.04, and below the 200-day MA of 1686.63, indicating a neutral trend. The MACD of 0.93 indicates Positive momentum. The RSI at 51.96 is Neutral, neither overbought nor oversold. The STOCH value of 77.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4556.
Kainos Laboratories, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥964.45B | 31.49 | 11.64% | 0.82% | 15.13% | 196.11% | |
71 Outperform | ¥3.25T | 23.87 | 8.98% | 1.22% | 9.24% | 16.68% | |
64 Neutral | ¥9.28B | 55.88 | ― | 2.53% | 3.28% | -30.16% | |
57 Neutral | ¥876.48B | 24.57 | 9.38% | 1.88% | -1.70% | -33.90% | |
54 Neutral | ¥275.39B | 20.39 | 4.38% | 2.03% | 2.47% | 164.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4556
Kainos Laboratories, Inc.
2,268.00
1,027.00
82.76%
JP:4543
Terumo
2,199.50
-362.93
-14.16%
JP:7747
Asahi Intecc Co
3,635.00
1,367.87
60.33%
JP:8086
Nipro
1,688.50
452.34
36.59%
JP:6869
Sysmex
1,405.50
-1,013.95
-41.91%
JP:368A
Kitazato Corporation
1,178.00
-580.70
-33.02%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.